liraglutide · Novo Nordisk Inc · NDA 022341
Victoza
Earliest generic entry, as listed
9 Jul 2037
Blocked by patent: US 9968659.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9968659 | — | 9 Jul 2037 |
| US 9968659 | use U-2313 | 9 Jan 2037 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 022341-00115 Jun 2026
- 25 Oct 2026Generic approved · 022341-00124 Feb 2026
- 25 Oct 2026Generic approved · 022341-00114 Jan 2026
- 25 Oct 2026Generic approved · 022341-00124 Feb 2026
- 25 Oct 2026Generic approved · 022341-0011 Jul 2026
- 25 Oct 2026Generic approved · 022341-00130 Mar 2026
- 25 Oct 2026Generic approved · 022341-00111 Mar 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022341 · 001 · RLD | solution, subcutaneous | 18MG/3ML (6MG/ML) | 9 Jul 2037 |
Expired or delisted (2)
- US 8114833 · — · 13 Feb 2026
- US 8114833 · substance, product · 13 Aug 2025